Right time, right place, right advice: AI-enabled medication reminder for in-home heart monitor

正确的时间、正确的地点、正确的建议：用于家用心脏监护仪的人工智能用药提醒

• 批准号: 10045765
• 金额: $ 6.29万
• 依托单位: HEARTFELT TECHNOLOGIES LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10045765
• 关键词: Right; time; right; place; advice

The catalyst behind the company's main product was a conversation with a heart transplant surgeon in 2015 that prompted a simple question: 'Do you know, that half the people I operate on wouldn't require surgery at all if they had reported their symptoms in time?'.Further research enabled the Heartfelt founders to unearth the hidden problem of "non-adherent' patients. These are mostly elderly people, often living alone, many with deteriorating mental capacity, who are unable to follow the advice given to them by their doctors. Instead of calling for help as their symptoms get worse, they end up as emergency hospital admissions.There are over 60M people globally with heart failure - a terminal illness with worse survival statistics than most cancers. The cost of treating them is substantial, roughly £1.7billion/year in the UK alone, most of which is spent delivering expensive and often preventable hospital treatments.Heartfelt's vision is to address this problem with an autonomous-monitoring-device that sits in the patient's home, measuring changes in foot-volume -- a key indicator of heart problems -- and triggering alerts and thus timely medical intervention. It has the potential to improve the life quality of millions of heart patients, and also to save the NHS money and reduce waiting time in A&E by freeing up hospital-beds.Heartfelt's monitor is fully automatic and requires no interaction with the patient. The foot-volume data is uploaded to the cloud and analysed using artificial intelligence, which watches for critical changes. It is complicated, cutting-edge technology, protected by patent but utterly simple to use. Pilot trials on hundreds of patients in the UK have demonstrated its effectiveness.By engaging a wide range of our patients and their carers in product development discussions, we found that a significant number of them would be open to the idea of the device itself providing reminders if their foot volume was increasing. That is how the idea for Aiona was born.The main aim of the project is to develop this "Alexa-like" feature, Aiona, to remind patients to take their medications when their foot volume trend raises alert on the main Heartfelt device. This would trigger a notification to the patient's care team who can review the data and decide if a medication prompt can be sent.Unlike daily medication-reminders, which patients become reminder-blind to within weeks, an occasional reminder when their symptoms are worsening is likely to be more effective.

该公司主要产品背后的催化剂是2015年与一名心脏移植外科医生的一次对话，那次对话引发了一个简单的问题：你知道吗，我做手术的人中，有一半人如果及时报告自己的症状，根本不需要手术。进一步的研究使发自内心的创始人发现了隐藏的问题，即患者不忠于患者。这些人大多是老年人，通常是独居，许多人的智力正在恶化，他们无法听从医生给他们的建议。当他们的症状恶化时，他们没有呼救，而是紧急入院。全球有超过6000万人患有心力衰竭--这是一种晚期疾病，其存活率比大多数癌症都要差。仅在英国，治疗这些疾病的成本就很高，大约每年17亿GB，其中大部分都花在了昂贵的、往往可以预防的医院治疗上。哈特费尔特的愿景是通过放置在患者家中的自动监测设备来解决这个问题，测量足部体积的变化--心脏问题的关键指标--并触发警报，从而及时进行医疗干预。它有可能提高数百万心脏病患者的生活质量，还可以通过腾出医院床位来节省NHS的资金和减少急诊室的等待时间。哈特费尔特的监护仪是全自动的，不需要与患者交互。足量数据被上传到云中，并使用人工智能进行分析，人工智能会监测关键变化。这是一项复杂的尖端技术，受专利保护，但使用起来非常简单。在英国对数百名患者进行的试点试验已经证明了它的有效性。通过让我们的患者和他们的护理人员参与产品开发讨论，我们发现相当多的人会接受这种设备本身可以提醒他们的脚量是否增加的想法。这就是Aiona这个想法的由来。该项目的主要目的是开发这种类似Alexa的功能，Aiona，当患者的足部体积趋势引起对主要心脏设备的警觉时，Aiona提醒患者服药。这将触发对患者护理团队的通知，他们可以查看数据并决定是否可以发送药物提示。与日常药物提醒不同，患者在几周内变得提醒失明，当他们的症状恶化时偶尔提醒可能更有效。